推荐产品
等級
pharmaceutical primary standard
API 家族
tetracycline
製造商／商標名
USP
mp
220-223 °C (lit.)
應用
pharmaceutical (small molecule)
形式
neat
儲存溫度
2-8°C
SMILES 字串
Cl.CN(C)[C@H]1[C@@H]2C[C@H]3C(=C(O)[C@]2(O)C(=O)C(C(N)=O)=C1O)C(=O)c4c(O)cccc4[C@@]3(C)O
InChI
1S/C22H24N2O8.ClH/c1-21(31)8-5-4-6-11(25)12(8)16(26)13-9(21)7-10-15(24(2)3)17(27)14(20(23)30)19(29)22(10,32)18(13)28;/h4-6,9-10,15,25,27-28,31-32H,7H2,1-3H3,(H2,23,30);1H/t9-,10-,15-,21+,22-;/m0./s1
InChI 密鑰
XMEVHPAGJVLHIG-FMZCEJRJSA-N
正在寻找类似产品? 访问 产品对比指南
一般說明
This product is provided as delivered and specified by the issuing Pharmacopoeia. All information provided in support of this product, including SDS and any product information leaflets have been developed and issued under the Authority of the issuing Pharmacopoeia.For further information and support please go to the website of the issuing Pharmacopoeia.
應用
Tetracycline hydrochloride USP reference standard, intended for use in specified quality tests and assays as specified in the USP compendia. Also, for use with USP monographs such as:
- Tetracycline Hydrochloride Ointment
- Tetracycline Hydrochloride Capsules
- Tetracycline Hydrochloride Tablets
- Tetracycline Hydrochloride Ophthalmic Ointment
- Tetracycline Hydrochloride Soluble Powder
- Tetracycline Hydrochloride and Novobiocin Sodium Tablets
生化／生理作用
作用机制：四环素通过细胞膜中的 proin 通道被动扩散，与 30S 核糖体结合，并通过阻止氨酰基 tRNA 进入 mRNA-核糖体复合物上的受体位点来抑制蛋白质合成。它也与细菌的 50S 核糖体亚基结合，改变膜并导致细胞内成分从细菌细胞中泄漏。通过洗涤可以逆转抑制作用，这表明起到抗菌作用的是可逆结合的抗生素，而不是不可逆结合的药物。
耐药性机制：这种作用通过细胞壁通透性的丧失而失活。
抗菌谱：包括对革兰氏阳性和革兰氏阴性细菌的广泛抗菌活性。
耐药性机制：这种作用通过细胞壁通透性的丧失而失活。
抗菌谱：包括对革兰氏阳性和革兰氏阴性细菌的广泛抗菌活性。
分析報告
These products are for test and assay use only. They are not meant for administration to humans or animals and cannot be used to diagnose, treat, or cure diseases of any kind.
其他說明
Sales restrictions may apply.
相關產品
产品编号
说明
价格
訊號詞
Warning
危險分類
Aquatic Acute 1 - Aquatic Chronic 2 - Eye Irrit. 2 - Repr. 2 - Skin Irrit. 2 - STOT SE 3
標靶器官
Respiratory system
儲存類別代碼
11 - Combustible Solids
水污染物質分類（WGK）
WGK 2
閃點（°F）
Not applicable
閃點（°C）
Not applicable
其他客户在看
Urszula Cegieła et al.
Acta poloniae pharmaceutica, 71(3), 485-495 (2014-10-01)
Clinical studies indicate that proton pump inhibitors (PPIs), used long-term in elderly patients, increase the risk of osteoporotic fractures, and decrease the anti-fracture efficacy of alendronate. The aim of the present study was to examine the effect of physical exercise
Mitsuhiro Yomoda et al.
Journal of biomaterials applications, 29(10), 1385-1393 (2015-01-01)
Previous studies have reported the excellent biocompatibility of calcium phosphate cement. However, calcium phosphate cement needs further improvement in order for it to promote bone replacement and eventual bone substitution, as it exhibits slow biodegradability and thus remains in the
Hanxiao Zhu et al.
Clinical orthopaedics and related research, 473(5), 1830-1839 (2015-03-05)
Steroids are a leading cause of femoral head osteonecrosis. Currently there are no medications available to prevent and/or treat steroid-associated osteonecrosis. Low-intensity pulsed ultrasound (LIPUS) was approved by the FDA for treating delayed union of bone fractures. Some studies have
Yuqin Qiao et al.
Biomaterials, 35(25), 6882-6897 (2014-05-28)
Rapid development of zinc biology has broadened the applications of Zn-incorporated biomaterials to tissue engineering but also raised concerns about the long-term safety of released Zn(2+) ions. Clinical success hinges on the amount of incorporated zinc and subsequent optimized release
E Amram et al.
Antimicrobial agents and chemotherapy, 59(2), 796-802 (2014-11-19)
Mycoplasma bovis isolates with decreased susceptibilities to tetracyclines are increasingly reported worldwide. The acquired molecular mechanisms associated with this phenomenon were investigated in 70 clinical isolates of M. bovis. Sequence analysis of the two 16S rRNA-encoding genes (rrs3 and rrs4
我们的科学家团队拥有各种研究领域经验，包括生命科学、材料科学、化学合成、色谱、分析及许多其他领域.
联系技术服务部门